Compare · CRVO vs NVO
CRVO vs NVO
Side-by-side comparison of CervoMed Inc. (CRVO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRVO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 5377.8x CRVO ($40.1M).
- Over the past year, CRVO is down 72.3% and NVO is down 14.1% - NVO leads by 58.2 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for CRVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for CRVO).
- Company
- CervoMed Inc.
- Novo Nordisk A/S
- Price
- $2.63-0.57%
- $47.52-2.31%
- Market cap
- $40.1M
- $215.46B
- 1M return
- +2.14%
- -6.72%
- 1Y return
- -72.29%
- -14.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 9
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRVO
- CervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SEC Form S-8 filed by CervoMed Inc.
- SEC Form 10-Q filed by CervoMed Inc.
- CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
- CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
- SEC Form EFFECT filed by CervoMed Inc.
- SEC Form 424B3 filed by CervoMed Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S